Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Products Lacking Good Subgroup Data Shouldn’t Be Approved, Patient, Medical Groups Tell FDA

This article was originally published in The Gray Sheet

Executive Summary

FDA should more strongly enforce requirements for adequate demographic subgroup representation in clinical trials for devices and other medical products, participants said at an April 1 meeting on collection and analysis of clinical trial subpopulation data to support product registration.

You may also be interested in...



Meeting Planned By FDA On Collecting Subgroup Data For Product Submissions

The agency plans a public meeting, required by the FDA Safety and Innovation Act, to chart progress on its action plan to improve industry data collection on demographic subgroups for product submissions and labeling for Feb. 29 at its Maryland headquarters.

Clinical Trial Diversity: ‘How Much More Evidence Do We Need To Move Forward?’

FDA seeks research ideas and plans to include demographic subgroup analyses in review templates as some stakeholders call for bolder action to change how companies conduct clinical trials.

Target Women’s Clinics, Keep Recruitment Open To Get More Women Into Trials, FDA Says In Guidance

FDA urges device firms to use a host of strategies to beef up enrollment of women in clinical trials to support device clearances and approvals, including targeting women’s clinics for recruitment efforts and revising enrollment criteria to include more females, in a final sex-specific clinical study guidance released Aug. 22.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel